Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 179Leukemia 162Lymphoma 116Lung Neoplasms 107Carcinoma, Non-Small-Cell Lung 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Central Nervous System Neoplasms 84Sarcoma 82Prostatic Neoplasms 81Ovarian Neoplasms 76Colorectal Neoplasms 71Head and Neck Neoplasms 70Leukemia, Myeloid, Acute 60Squamous Cell Carcinoma of Head and Neck 54Rectal Neoplasms 54Neuroblastoma 52Colonic Neoplasms 52Multiple Myeloma 51Uterine Cervical Neoplasms 47Brain Neoplasms 46Lymphoma, Large B-Cell, Diffuse 45Leukemia, Lymphocytic, Chronic, B-Cell 41Carcinoma, Ovarian Epithelial 41Burkitt Lymphoma 41Astrocytoma 40Glioblastoma 39Fallopian Tube Neoplasms 39Neoplasm Metastasis 38Congenital Abnormalities 37Lymphoma, Follicular 36

Interventions

tremelimumab 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × NETWORK × Advanced Rare Tumours × Clear all
NCT02879162 2025-03-07

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Canadian Cancer Trials Group

Phase 2 Completed
140 enrolled 9 charts

Advanced Rare Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡